Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats.

  title={Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats.},
  author={Tomonori Nakanishi and Tatsuaki Morokata and Takahisa Noto and Kaori Kubo and Hitomi Umeno and Fumitaka Kinugasa and Yoshiteru Eikyu and Yoshihiro Kozuki and Nobuo Seki},
  journal={International immunopharmacology},
  volume={10 11},
Chronic allograft nephropathy (CAN) is a major cause of late allograft loss. One morphological characteristic of CAN is renal interstitial fibrosis. Mycophenolate mofetil (MMF), the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitor, has been reported to attenuate the progression of renal interstitial fibrosis. However, the question of whether the newly synthesized IMPDH inhibitors with structures different from MMF have an antifibrotic effect remains unanswered. We evaluated the… Expand
Vimentin expression is required for the development of EMT-related renal fibrosis following unilateral ureteral obstruction in mice.
Vimentin inhibition decreases fibrosis following UUO by possibly altering β-catenin localization and downstream signaling, and vim-silenced HK-2 cell lines undergoing EMT were shown to have decreased cellular migration during wound healing. Expand
Proteomic landscape of TGF-β1-induced fibrogenesis in renal fibroblasts
It is concluded that TGF-β1-induced fibrogenesis in renal fibroblasts is an intracellular metabolic disorder and is inherently coupled with inflammation mediated by chemokines and may guide development of novel anti-fibrotic therapies in a network pharmacology approach. Expand
Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets
The purpose of this review is to summarize the existing body of knowledge regarding activation of cytokine pathways and infiltration of inflammatory cells as a starting point for developing novel antifibrotic therapies to prevent progression of CKD. Expand


Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.
The results suggest that BMS-566419 and other chemically synthesized IMPDH inhibitors have beneficial pharmacological effects similar to those of MMF, and are potential pharmaceutical candidates in transplant indications. Expand
Mycophenolic acid inhibits albumin-induced MCP-1 expression in renal tubular epithelial cells through the p38 MAPK pathway
The inhibitory effect of MPA on MCP-1 expression by albumin-induced renal tubular epithelial cells was investigated, and the roles of p38 mitogen-activated protein kinase (p38 MAPK) pathway were explored. Expand
Effects of Mycophenolate Mofetil and Lisinopril on Collagen Deposition in Unilateral Ureteral Obstruction in Rats
MMF and the ACE inhibitor lisinopril attenuated the progression of the fibrogenic process of UUO in an equivalent manner and the combination of both drugs did not add any further improvement in the collagen content. Expand
Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
The data suggest that MMF treatment ameliorates early renal injury via the inhibition of oxidative stress and overexpression of ICAM-1, MCP-1 and TGF-beta1 in renal tissue in diabetic rats. Expand
Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction.
It is indicated that the renin-angiotensin system has a major role in the pathogenesis of the tubulointerstitial fibrosis of obstructive nephropathy. Expand
Effects of mycophenolate mofetil on renal interstitial fibrosis after unilateral ureteral obstruction in rats
It is suggested that the reduction of interstitial MyoF infiltration may be an important event by which MMF prevents renal injury caused by UUO and MMF could be used to limit the progression of renal fibrosis. Expand
Antifibrotic actions of mycophenolic acid
There is a growing body of evidence pointing to therapeutic applications of MMF other than immunosuppression, in particular the prevention of fibrosis. Expand
Molecular and cellular pathophysiology of obstructive nephropathy
Future efforts to prevent the consequences of congenital urinary tract obstruction must account for the dual effects of obstruction: interference with normal renal development and progression of irreversible tubulointerstitial injury. Expand
The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways.
It is suggested that various immunosuppressants affected differentially TGF-beta1 and Smads signal pathways in rat VSMC and kidney grafts and prevented CAN progression through down-regulation of the expression of smad2 and smad3, with increased smad7 production. Expand
Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney.
Enalapril treatment ameliorates the tubulointerstitial fibrosis of the affected kidney in UUO and may be due to the severe reduction in monocytes/macrophages capable of secreting the profibrotic factor TGF-beta 1. Expand